Deficiency of carbamylphosphate synthetase [DS:H00164] Deficiency of ornithine transcarbamylase [DS:H00187] Deficiency of argininosuccinic acid synthetase [DS:H00185] Urea cycle disorders [DS:H01398]
Comment
Active form of prodrug: Phenylacetate [CPD:C07086]
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16AX Various alimentary tract and metabolism products
A16AX03 Sodium phenylbutyrate
D05868 Sodium phenylbutyrate (JAN/USP) <JP/US>
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Sodium Phenylbutyrate
D05868 Sodium phenylbutyrate (JAN/USP)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D05868 Sodium phenylbutyrate (JAN/USP)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D05868
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D05868
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
D05868
Prodrugs [br08324.html]
D05868